Clover Health Investments Corp (CLOV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Clover Health Investments Corp (CLOV) Stock Forecast
Analysts expect Clover Health Investments (CLOV) to earn $0.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.99B. Of 5 analysts, 3 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 60% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 2 | 40.0% |
| Hold | 2 | 40.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 28.6% and revenue estimates rise 22.4%.
- Fiscal year ending Dec 31, 2026
- $0.14
- EPS consensus, revenue $2.99B
- Fiscal year ending Dec 31, 2027
- $0.18
- EPS consensus, revenue $3.66B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.14 | $0.14 to $0.14 | 1 | $2.99B | $2.98B to $2.99B | 5 |
| Dec 31, 2027 | $0.18 | $0.18 to $0.18 | 1 | $3.66B | $3.46B to $3.80B | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.05 for the quarter ending Dec 31, 2026 to $0.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.05 | -$0.05 to -$0.05 | 7 | $750.14M | $713.56M to $779.63M | 7 |
| Mar 31, 2027 | $0.08 | $0.08 to $0.08 | 1 | $928.62M | $906.10M to $960.58M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 0.0% |
| Fiscal year ending Dec 31, 2027 | $0.18 | $0.15 | $0.15 | $0.15 | $0.15 | +20.0% |
| Quarter ending Mar 31, 2027 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | 0.0% |
Frequently Asked Questions About CLOV
What is the CLOV stock forecast?
Consensus analyst estimates put Clover Health Investments's EPS at $0.14 for the fiscal year ending Dec 31, 2026, on revenue of $2.99B. The consensus rating from 5 analysts is Buy.
How do analysts rate CLOV stock?
Of 5 analysts covering Clover Health Investments, 1 rates it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CLOV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.14, with estimates from $0.14 to $0.14 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.18, with estimates from $0.18 to $0.18 from 1 analyst.
What revenue do analysts expect from Clover Health Investments next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.99B, with estimates from $2.98B to $2.99B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.66B, with estimates from $3.46B to $3.80B.
How many analysts cover CLOV?
5 analysts rate Clover Health Investments stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
CLOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors